retatrutide phase 2 trial obesity nejm 2023 results Retatrutide (not yet approved in US but people using anyway) promises even potentially greater weight loss amongst the GLP1 drugs. https://www.nejm .org/doi/full/10.1056/NEJMoa2301972 retatrutide phase 2 nejm weight

Bulk-sourced compounds carry risks of contamination, incorrect potency, and unknown identity, with no quality control or regulatory oversight

No medical, therapeutic, diagnostic or preventive use is claimed or implied

Reelin differentially shapes dendrite morphology of medial entorhinal cortical ocean and island cells

Do not make assumptions about whether a dose is still suitable for use always defer to the trial team

Physiological changes associated with enhanced cold resistance during maize ( Zea mays ) germination and seedling growth in response to exogenous calcium

First as secondary endpoints, then as trials explicitly designed for kidney disease: CREDENCE (Perkovic et al, NEJM 2019 | NephJC Summary), DAPA-CKD (Heerspink et al, NEJM 2020 | NephJC Summary), and EMPA-KIDNEY (Herrington et al, NEJM 2022 | NephJC Summary), each progressively widening eligibility